ABSI
ABSI
NASDAQ · Biotechnology

Absci Corp

$10.03
-0.05 (-0.45%)
Financial Highlights (FY 2026)
Revenue
3.26M
Net Income
-134,000,206
Gross Margin
Profit Margin
-4,113.7%
Rev Growth
-21.3%
D/E Ratio
0.00
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 58.4% 58.4%
Operating Margin -4,297.0% -3,867.3% -17.8% -17.1%
Profit Margin -4,113.7% -3,908.0% -15.3% -17.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 3.26M 4.15M 58.57M 57.07M
Gross Profit 34.21M 33.33M
Operating Income -140,173,183 -160,360,829 -10,406,862 -9,769,969
Net Income -134,000,206 -153,298,824 -8,944,093 -9,875,873
Gross Margin 58.4% 58.4%
Operating Margin -4,297.0% -3,867.3% -17.8% -17.1%
Profit Margin -4,113.7% -3,908.0% -15.3% -17.3%
Rev Growth -21.3% -21.3% +10.3% +2.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.64M 2.64M 100.48M 118.62M
Total Equity 574.98M 574.98M 298.85M 311.81M
D/E Ratio 0.00 0.00 0.34 0.38
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -126,314,409 -152,534,242 -15,160,350 -13,058,914
Free Cash Flow -10,726,027 -11,756,277